The US FDA has approved a label extension for UCB’s Cimzia (certolizumab pegol) for adults with moderate-to-severe plaque psoriasis, marking the company’s entry into immuno-dermatology ...
NICE has recommended in draft guidance that UCB’s Cimzia can receive regular NHS funding for plaque psoriasis, but decided that Almirall’s rival Ilumetri does not represent good value for money.
Another TNF inhibitor, certolizumab (Cimzia; UCB), which is approved for Crohn's disease and rheumatoid arthritis, showed good efficacy in Phase II psoriasis trials 2. However, no development of ...
Dermira, Inc. (NASDAQ:DERM) and UCB (Euronext:UCB) today announced the companies have agreed to end their development and commercialization agreement for CIMZIA (certolizumab pegol) in psoriasis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback